WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009137602) THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/137602    International Application No.:    PCT/US2009/043015
Publication Date: 12.11.2009 International Filing Date: 06.05.2009
IPC:
A61K 31/715 (2006.01), A61K 36/00 (2006.01), A61K 38/16 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street 5th Floor Oakland, CA 94607-5200 (US) (For All Designated States Except US).
SULLIVAN, Benjamin [US/US]; (US) (For US Only).
SCHMIDT, Tannin, A. [US/US]; (US) (For US Only).
SULLIVAN, David, A. [US/US]; (US) (For US Only).
SCHEPENS EYE RESEARCH INSTITUTE [US/US]; 20 Staniford Street Boston, Massachusetts 02114 (US) (For All Designated States Except US)
Inventors: SULLIVAN, Benjamin; (US).
SCHMIDT, Tannin, A.; (US).
SULLIVAN, David, A.; (US)
Agent: WARREN, William, L.; (US)
Priority Data:
61/051,112 07.05.2008 US
Title (EN) THERAPEUTIC MODULATION OF OCULAR SURFACE LUBRICATION
(FR) MODULATION THÉRAPEUTIQUE DE LA LUBRIFICATION DE LA SURFACE OCCULAIRE
Abstract: front page image
(EN)Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound iα combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.
(FR)La présente invention concerne des compositions pharmaceutiques acceptables au plan ophtalmique comprenant un composé induisant PRG4 combiné avec PRG4 (y compris des fragments de lubrifiants, des homologues ou des isoformes associés) et des procédés permettant d'utiliser ces compositions. Le composé induisant PRG4 contenu dans la composition pharmaceutique décrite dans l'invention permet de réguler de manière positive l'expression de PRG4 et sa localisation dans la surface occulaire pour une lubrification limite de surface efficace. Dans certains modes de réalisation, les compositions pharmaceutiques décrites dans l'invention sont utilisées pour traiter des affections ophtalmiques, par exemple, une carence de limite occulaire et les symptômes qui lui sont associés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)